ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis

StatusRecruiting

PhaseNot specified

Sponsorargenx

Started2025-12-19

View on ClinicalTrials.gov ↗

Amendment history

2026-08-20

Study Status, Contacts/Locations v8

Trial sites expanded: 30 → 35 locations

2026-07-28

Study Status, Study Description, Arms and Interventions, Contacts/Locations, References v7

Trial arms changed: 1 → 2

Trial sites expanded: 18 → 29 locations

InterventionsEfgartigimod IV (Biological), Empasiprubart IV (Biological)→Efgartigimod IV (Biological), Efgartigimod PH20 SC PFS (Biological), Empasiprubart IV (Biological), Placebo IV (Other)

Study description+324 characters

[...] artigimod (https://www.clinicaltrials.gov/study/NCT07284420) NCT07673627 - Adapt Forward 2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis (https://clinicaltrials.gov/study/NCT07673627) More information can be found here: https://clinicaltrials [...]

2026-06-11

Study Status, Contacts/Locations v6

Trial sites expanded: 15 → 18 locations

2026-06-02

Study Status, Contacts/Locations v5

Trial sites expanded: 10 → 15 locations

Study sitesdetails revised at 5 of 15 sites

2026-05-29

Study Status, Contacts/Locations v4

Study sites10→15

2026-04-22

Study Status, Contacts/Locations v3

Trial sites expanded: 5 → 10 locations

2026-02-17

Study Status, Contacts/Locations v2

Study sites3→5

2026-01-09

Not Yet Recruiting→Recruiting Study Status, Study Description, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2025-12→confirmed 2025-12-19

Study sites0→3

Study description+65 characters

[...] e ISAs. Following ISAs are included in this platform study: NCT07284420 - ADAPT Forward 1 - a study to evaluate empasiprubart IV as ad [...] enia gravis with a partial clinical response to efgartigimod (https://www.clinicaltrials.gov/study/NCT07284420)

2025-12-08

Original filing

Argenx

56 trials monitored

See 2 trials at risk

Myasthenia Gravis

187 trials monitored

See 7 trials at risk

ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.

Trial Details

NCT Number	NCT07294170
Lead Sponsor	argenx
Conditions	Myasthenia Gravis, MG, gMG, Generalized Myasthenia Gravis, Generalized Myasthenia Gravis (gMG), AChR-Ab Seropositive Generalized Myasthenia Gravis
Enrollment	70 participants
Start Date	2025-12-19
Primary Completion	2028-03-07 (estimated)
Study Completion	2028-03-07 (estimated)
Updated on ClinicalTrials.gov	2026-09-24